The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows
International Journal of Molecular Sciences · 01.01.2023 · 24 (1) · 764
DOI: 10.3390/ijms24010764 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.01.2023. Verfasst von Vera Loizzi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit IRCSS Istituto Tumori "Giovanni Paolo II", Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", 70124 Bari, …. Hauptthemen laut MEDLINE: Breast Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
All cancers develop as a result of mutations in genes. DNA damage induces genomic instability and subsequently increases susceptibility to tumorigenesis. Women who carry mutations of BRCA 1 and BRCA2 genes have an augmented risk of breast and ovarian cancer and a markedly augmented probability of dying because of cancer compared to the general population. As a result, international guidelines recommend that all BRCA1\2 mutation carriers be offered risk-reducing bilateral salpingo-oophorectomy at an early age to reduce the risk of cancer and decrease the mortality rate of this high-risk population. NCCN guidelines recommend risk-reducing bilateral salpingo-oophorectomy in pre-menopausal women, between 35–40 years in BRCA1 mutation carriers and between 40–45 years in BRCA2 mutation carriers. Unfortunately, the well-documented reduction of cancer risk is counterbalanced by early sterility and premature ovarian failure with an early onset of secondary menopausal syndromes such as neuromotor, cardiovascular, cognitive and urogenital deficiency. Hormonal replacement therapy significantly compensates for hormonal deprivation and counteracts menopausal syndrome morbidity and mortality; however, some data suggest a possible correlation between hormonal medications and cancer risk, especially in BRCA1\2 carriers who undergo long-term regimens. Conversely, short-term treatment before the age of natural menopause does not appear to increase the cancer risk in BRCA1 mutation carriers without a personal history of breast cancer after prophylactic surgery. Few data are available on BRCA2 mutation carriers and more well-designed studies are needed. In conclusion, clinicians should propose short-term hormone replacement therapy to BRCA 1 carriers to counteract hormonal deprivation; personalized counselling should be offered to BRCA2 mutation carriers for a balance between the risks and benefits of the treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Unit IRCSS Istituto Tumori "Giovanni Paolo II", Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", 70124 Bari, Italy.
- Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of "Aldo Moro", 70124 Bari, Italy.
- Section of Pathology, Department of Emergency and organ transplantation (DETO), University of Bari "Aldo Moro", 70124 Bari, Italy.
- Gynecologic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy.
- Pathology Unit, FPO-IRCCS Candiolo Cancer Institute, 10060 Candiolo, Italy.
- Department of Medical Sciences, University of Turin, 10124 Turin, Italy.
ORCID-Profile: Vera Loizzi, Miriam Dellino, Marco Cerbone, Gerardo Cazzato, Gianluca Raffaello Damiani, Erica Silvestris, Ettore Cicinelli, Eliano Cascardi, Gennaro Cormio
Zitieren
APA
Loizzi, V., Dellino, M., Cerbone, M., Arezzo, F., Cazzato, G., Damiani, G. R., Pinto, V., Silvestris, E., Kardhashi, A., Cicinelli, E., Cascardi, E., & Cormio, G. (2023). The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows. International Journal of Molecular Sciences, 24(1), 764. https://doi.org/10.3390/ijms24010764
Vancouver
Loizzi V, Dellino M, Cerbone M, Arezzo F, Cazzato G, Damiani GR, et al. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows. International Journal of Molecular Sciences. 2023;24(1):764. doi:10.3390/ijms24010764
BibTeX
@article{Loizzi2023,
author = {Loizzi, Vera and Dellino, Miriam and Cerbone, Marco and Arezzo, Francesca and Cazzato, Gerardo and Damiani, Gianluca Raffaello and Pinto, Vincenzo and Silvestris, Erica and Kardhashi, Anila and Cicinelli, Ettore and Cascardi, Eliano and Cormio, Gennaro},
title = {The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {1},
pages = {764},
doi = {10.3390/ijms24010764}
}
EUVIMED